Core One Labs Inc. CEO Joel Shacker said his company has discovered a new method to affordably produce psilocybin | Rob Kruyt
Vancouver drug-research companies are seeking cheaper ways to produce psychedelic mushrooms, or the active ingredient psilocybin, to cater to new demand.
One longer-term trend has been for pharmaceutical companies to invest in creating psilocybin-based drugs that treat depression, addictions, post-traumatic stress disorder and other conditions.
Health Canada in January launched what it calls a “special access program” that allows physicians to request that government grant patients access to psilocybin, which is otherwise illegal to possess and produce.
Government decisions on these requests are to be made case by case and
→ Continue reading at BIV